Spark Therapeutics Top Management
Spark Therapeutics employs about 368 people. The company is managed by 30 executives with a total tenure of roughly 271 years, averaging almost 9.0 years of service per executive, having 12.27 employees per reported executive. Evaluation of Spark Therapeutics' management performance can provide insight into the firm performance.
| Jeffrey Marrazzo CEO CEO, Co-Founder, Director |
| Steven Altschuler Chairman Chairman of the Board |
Spark |
Spark Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.107) % which means that it has lost $0.107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1515) %, meaning that it created substantial loss on money invested by shareholders. Spark Therapeutics' management efficiency ratios could be used to measure how well Spark Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Spark Therapeutics Workforce Comparison
Spark Therapeutics is considered to be number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 159,031. Spark Therapeutics adds roughly 368 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Spark Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spark Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spark Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Spark Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephen Webster over a year ago Payment of 635 shares by Stephen Webster of Spark Therapeutics subject to Rule 16b-3 |
Spark Therapeutics Notable Stakeholders
A Spark Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Spark Therapeutics often face trade-offs trying to please all of them. Spark Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Spark Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jennifer Wellman | Co-Founder and Head of Regulatory Strategy | Profile | |
| Fraser Wright | Co-Founder and CTO | Profile | |
| Jeffrey Marrazzo | CEO, Co-Founder, Director | Profile | |
| Steven Altschuler | Chairman of the Board | Profile | |
| Katherine High | President Chief Scientific Officer, Director | Profile | |
| Stephen Webster | CFO | Profile | |
| John Furey | COO | Profile | |
| Robert Perez | Director | Profile | |
| Lars Ekman | Independent Director | Profile | |
| Lorris Betz | Director | Profile | |
| Elliot Sigal | Independent Director | Profile | |
| Vincent Milano | Independent Director | Profile | |
| Lota Zoth | Director | Profile | |
| Elliott Sigal | Independent Director | Profile | |
| Anand Mehra | Independent Director | Profile | |
| Charles Sigal | Independent Director | Profile | |
| Romuald Corbau | Translational Research Lead | Profile | |
| Carol GrevePhilips | Head of Business Development and Strategy | Profile | |
| Morgan Molloy | Head of U.S. Commercial | Profile | |
| Joseph Barge | General Counsel and Head of Business Administration | Profile | |
| Rogerio Coelho | Chief Commercial Officer | Profile | |
| Guang Qu | Head of Process Development | Profile | |
| Daniel Takefman | Head of Regulatory Affairs | Profile | |
| Rogerio Vivaldi | Chief Commercial Officer | Profile | |
| Diane Blumenthal | Head of Technical Operations | Profile | |
| Daniel Faga | Chief Business Officer | Profile | |
| Linda Hearne | Financial Operations and Analysis Lead | Profile | |
| Paul Gil | Regulatory CMC and Quality Assurance Lead | Profile | |
| Federico Mingozzi | Chief Scientific Officer | Profile | |
| Lisa Dalton | Head - Human Resources | Profile |
Spark Therapeutics Workforce Analysis
Traditionally, organizations such as Spark Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Spark Therapeutics within its industry.Spark Therapeutics Manpower Efficiency
Return on Spark Therapeutics Manpower
| Revenue Per Employee | 158K | |
| Revenue Per Executive | 1.9M | |
| Net Loss Per Employee | 628.3K | |
| Net Loss Per Executive | 7.7M | |
| Working Capital Per Employee | 786.7K | |
| Working Capital Per Executive | 9.6M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Spark Therapeutics information on this page should be used as a complementary analysis to other Spark Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Spark Stock
If you are still planning to invest in Spark Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spark Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |